Busmann A - Search Results

1

A three-step purification strategy for isolation of hamster TIG2 from CHO cells: characterization of two processed endogenous forms.

Busmann A, Walden M, Wendland M, Kutzleb C, Forssmann WG, John H. Busmann A, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Nov 25;811(2):217-23. doi: 10.1016/j.jchromb.2004.09.006. J Chromatogr B Analyt Technol Biomed Life Sci. 2004. PMID: 15522723

2

Characterization of human circulating TIG2 as a ligand for the orphan receptor ChemR23.

Meder W, Wendland M, Busmann A, Kutzleb C, Spodsberg N, John H, Richter R, Schleuder D, Meyer M, Forssmann WG. Meder W, et al. Among authors: busmann a. FEBS Lett. 2003 Dec 18;555(3):495-9. doi: 10.1016/s0014-5793(03)01312-7. FEBS Lett. 2003. PMID: 14675762 Free article.

3

Identification and functional characterization of hemorphins VV-H-7 and LVV-H-7 as low-affinity agonists for the orphan bombesin receptor subtype 3.

Lammerich HP, Busmann A, Kutzleb C, Wendland M, Seiler P, Berger C, Eickelmann P, Meyer M, Forssmann WG, Maronde E. Lammerich HP, et al. Among authors: busmann a. Br J Pharmacol. 2003 Apr;138(8):1431-40. doi: 10.1038/sj.bjp.0705177. Br J Pharmacol. 2003. PMID: 12721098 Free PMC article.

4

Discovery of novel regulatory peptides by reverse pharmacology: spotlight on chemerin and the RF-amide peptides metastin and QRFP.

Kutzleb C, Busmann A, Wendland M, Maronde E. Kutzleb C, et al. Among authors: busmann a. Curr Protein Pept Sci. 2005 Jun;6(3):265-78. doi: 10.2174/1389203054065419. Curr Protein Pept Sci. 2005. PMID: 15974952 Review.

5

Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide.

Forssmann WG, The YH, Stoll M, Adermann K, Albrecht U, Tillmann HC, Barlos K, Busmann A, Canales-Mayordomo A, Giménez-Gallego G, Hirsch J, Jiménez-Barbero J, Meyer-Olson D, Münch J, Pérez-Castells J, Ständker L, Kirchhoff F, Schmidt RE. Forssmann WG, et al. Among authors: busmann a. Sci Transl Med. 2010 Dec 22;2(63):63re3. doi: 10.1126/scitranslmed.3001697. Sci Transl Med. 2010. PMID: 21178138 Clinical Trial.

6

Stability and cleavage conditions of (2-furyl)-L-alanine-containing peptides.

Schulz A, Busmann A, Klüver E, Schnebel M, Adermann K. Schulz A, et al. Among authors: busmann a. Protein Pept Lett. 2004 Dec;11(6):601-6. doi: 10.2174/0929866043406238. Protein Pept Lett. 2004. PMID: 15579131

7

Peptidomic analysis of human peripheral monocytes persistently infected by Chlamydia trachomatis.

Krausse-Opatz B, Busmann A, Tammen H, Menzel C, Möhring T, Le Yondre N, Schmidt C, Schulz-Knappe P, Zeidler H, Selle H, Köhler L. Krausse-Opatz B, et al. Among authors: busmann a. Med Microbiol Immunol. 2007 Jun;196(2):103-14. doi: 10.1007/s00430-006-0033-y. Epub 2007 Jan 6. Med Microbiol Immunol. 2007. PMID: 17206452

8

Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.

Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Havrdova T, Heerspink HJL, Kooy A, Laverman GD, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Petrie JR, Ruggenenti PL, Rutters F, Rychlík I, Siwy J, Spasovski G, Speeckaert M, Trillini M, Zürbig P, von der Leyen H, Rossing P; PRIORITY investigators. Tofte N, et al. Lancet Diabetes Endocrinol. 2020 Apr;8(4):301-312. doi: 10.1016/S2213-8587(20)30026-7. Epub 2020 Mar 2. Lancet Diabetes Endocrinol. 2020. PMID: 32135136 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8 results

Search Page